Jane Street Group, LLC Mirati Therapeutics, Inc. Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$75.82 - $150.97 $144,058 - $286,843	1,900 Added 6.53%	31,000 $2.55 Million
Q4 2021 Feb 15, 2022	SELL	$132.01 - $190.29 $4.67 Million - $6.74 Million	-35,400 Reduced 54.88%	29,100 $4.27 Million
Q3 2021 Nov 16, 2021	BUY	$132.13 - $177.45 $1.63 Million - $2.18 Million	12,300 Added 23.56%	64,500 $11.4 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $5.18 Million - $6.47 Million	36,000 Added 222.22%	52,200 $8.43 Million
Q1 2021 May 18, 2021	SELL	$158.92 - $221.61 $810,491 - $1.13 Million	-5,100 Reduced 23.94%	16,200 $2.78 Million
Q4 2020 Feb 17, 2021	SELL	$162.05 - $240.27 $7.28 Million - $10.8 Million	-44,900 Reduced 67.82%	21,300 $4.68 Million
Q3 2020 Nov 17, 2020	BUY	$113.26 - $167.27 $4.76 Million - $7.03 Million	42,000 Added 173.55%	66,200 $11 Million
Q2 2020 Aug 17, 2020	SELL	$72.01 - $120.39 $2.54 Million - $4.25 Million	-35,300 Reduced 59.33%	24,200 $2.76 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $3.75 Million - $6.25 Million	53,800 Added 943.86%	59,500 $4.57 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $403,332 - $734,502	5,700 New	5,700 $735,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.